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tion differed between the two groups. Patients with RF were less likely to present with 
chest pain (65.5% vs. 76.5%, p=.OZ) and syncope (6 vs. 13.8%, p = .04), but were more 
likely to have hypotension (35.4 vs. 19.9%. p = .OOll) and an altered mental status (18.3 
vs. 9.5%, p = .Ol). Patients with RF were also more likely to suffer vascular complications 
of AAD including mesenteric ischemia (20.2 vs 2.2% p <.OOOl) and limb ischemia (20.0 
vs. 7.9%, p = .0003). Finally, RF on presentation adversely affected suwival (mortality 
39.3 vs. 21.4%, p = .0002). 
Conclusions: The presence of RF identifies a subgroup of patrents at particularly high risk 
for vascular complications and death. This simple marker should prompt evaluation for 
visceral and limb ischemia to ensure the use of appropriate medical and surgical strate- 
gles lo reduce morbidity and mortality from AAD. 
1034-l 43 Endovascular Stent-Graft Repair of Descending 
Thoracic Aortic Penetrating Atherosclerotic Ulcers: 
Mid-Term Results 
Philippe Darners, D. Craig Miller, R. Scott Mitchell, Stephen T. Kee, Lynn Chagonjlan, 
Michael D. Dake, Stanford University School of Medicine, Stanford, CA 
Background: The objective of this study was to determine the effectiveness of endovas- 
cular stent-graft (S-G) treatment of patients wtth descending thoracic aortic penetrating 
atherosclerotic ulcers (PAU) and identify risk factors for treatment failure. Methods 
Between March 1993 and January 2001, endovascular repair of descending thoracic aor- 
tic PAU with first- (custom-fabricated) and second generation (commercial) stem-grafts 
was performed in 26 patients (mean age 70 years, range 55.85), six (23%) of whom had 
rupture. Fourteen patients (54%) were judged not lo be reasonable surgical candidates 
for a conventional open operative procedure because of various comorbidities. Follow-up 
was 100% complete (average 51 months. max 114 mo, 12 patients remaining at risk at 5 
years). Oulcome variables considered in the multivariable analysis included all deaths 
and treatment failure (composite end-point comprising endoleak, stent-graft mechanical 
fault, late aortic event, reintewention, and/or aortic-related or sudden, unexplained late 
death). Results: Three patients (12%) dk?d within 30 days, and 2 had an early type I 
endoleak. No surgical conversions were necessary Procedural success rate was 92% at 
the time of discharge. Actuarial survival estimates at I, 3 and 5 year were 85*8%, 
76+8% and 70*10%. respectively. Actuarial freedom from treatment failure at the same 
times was 61+8%, 71~9% and 65*10%. Multivariable analysis identified previous stroke 
and female gender as independent risk factors for death. For treatment failure, these pre- 
dictors were maximal aortic diameter and female gender. Conclusions: These mid-term 
results indicate that andovascular S-G repair is effective in selected high surgical risk, 
elderly patients with PAU located in the descending thoracic aorta, as such localized 
pathology is an ideal target for a S-G. Strict serial radiological imaging follow-up is man- 
datory lo detect late complications. 
1034-l 44 Perioperative Myocardial lschemic Complications 
Following Abdominal Aortic Aneurysm Repair Lead to 
Substantially Increased In-Hospital Costs 
Kristian B. Filion, Louise Pilate, Seema Haider, Mark J. Eisenberg, Jewish General 
Hospital/McGill University, Montreal, PQ, Canada 
Background: Perioperative myocardial ischemlc complications (PMICs) have serious 
clinical implications for patients undergoing abdominal aortic aneurysm repair (AAA). Our 
objective was to determine the magnitude of the cost increase with an episode of PMIC 
followina AAA repair. _ 
Methods: We compared the cost of treating 1,057 consecutive patients undergoing AAA 
reDair between 1997 and 2001 at 6 U.S. and 4 Canadian hosDitals (n=505 and n=551. 
I  
respectively). PMIC was defined as the c~ccurrance of perioperative congestive heari fail- 
ure (CHF). myocardial infarction (Ml), or death. Patients wars subdivided into 2 catego- 
ries according to the occurrence of perioperative complications: 1) no complications 
(81.3%). and 2) PMlCs (18.7%). Participating hospitals used the same cc~st accounting 
system to provide patient-level clinical and cost data. Canadian costs were converted lo 
U.S. dollars using purchasing power parities. 
Results: Patlents experiencing an episode of PMIC were more likely lo be wmen and 
the elderly (27.9% vs 16.0%, p<O.OOOl; age<75: 16.2% vs age>=75: 22.5%, p=O.Ol). 
Patients experiencing PMlCs were also mire likely to be admitted for non-elective sur- 
gery than those admitted for elective surgery (25.5% vs 11.8%, p<O.OOOl). Rates of dia- 
betes mellitus were higher among those experiencing PMlCs (29.1% vs. 17.8% p=O.O2), 
while rates of prior Ml, hypothyroidism, and chronic obstructive pulmonary disorders 
(COPD) were similar (P=NS for all three conditions). Once admilted. patients with PMIC 
stayed an average of i.6 days longer in hospital than patients without’PMIC (pcO.0001). 
Both US. and Canadian patlen& experiencina PMlCs had a sianificantlv hlaher cost of _ ._ 
treatment compared with those without PMlCs (U.S.: median $22,823 vs $12.786. mean 
545,770*7,205 vs $19,441+990, p-zO.0001; Canada: median 514,850 vs 57,295, mean 
520,862*1,802 vs 510,868+541, pcO.0001). After controlling for clinical and demo- 
graphic differences, there was a 68% increase in cost among U.S. patients with PMlCs 
and a 56% increase among Canadian patients. 
Conclusion: PMIC following AAA repair leads to substantially higher in-hospital costs of 
treatment and should be prevented. 
1034-l 45 Hospital Readmissions Following Abdominal Aortic 
Aneurysm Repair 
Laura C. Gioia. Kristian B. Filion, Seema Haider, Louise Pilote, Mark J. Eisenberg, 
Jewish General Hospital/McGill University, Montreal, PO, Canada 
Background: In-hospital outcomes associated with abdominal aorlic aneurysm (AAA) 
reparr are well-described. However, little is known about post-discharge readmission 
rates, subsequent mortality, and cost. 
Methods: We examined 206 consecutive patients who underwent AAA repair at 2 Ameri- 
can hospitals between 1997 and 2001. Index hospitalization and 6-month readmission 
data were extracted from a resource and cost accounting system used by both hospitals. 
Results: Among the 206 patients, 183 survived until discharge (mortality rate 11.2%: IO 
deaths after elective repair (6.4%) and 13 after non-elective repair (26.5%)). Among the 
147 elective patients who survived until discharge, 21.1 % (311147) were readmitted 
within the subsequent 6 months. Among the 36 non-elective patients, 36.1% (13/36) 
were readmitted. Age and gender distribution were similar among readmitted patients 
and non-readmitted patients (72.5 * 9.5 vs. 73.0 * 10.1 years, p=NS and 68.2% vs. 
69.1% male, p=NS, respectwely). More than two-thirds of the readmissions occurred dur- 
ing the first month following discharge (mean 36.3 + 46.7 days, median 15.5). The mor- 
tality rate among readmitted patients was 11.4%: 6.5% among elective patients and 
23.1% among non-elective patients. For each readmission, the mean cost was 510,547 * 
1,993 (median 54,464.8) and mean length of stay was 8.5 * 12.6 days (median 4.0). The 
mean number of readmissions per patient was 2.2 f 1.8 times (median 1 .O). The total 
per-patient cost for all readmisslons during the first 6 months followng AAA repair was 
519,460 + 4,863 (median $6,895.5); the total length of stay was 15.5 f 21 days (median 
8). Overall, readmlssions during the 6 months following AAA repalr accounted for a cost 
>50% Over and above the cost of the Index hospitalization (mean 532,217.g * 7,015.9, 
median 18,229s) 
Conclusions: Hospital readmissions within the 6 months following AAA repair occur com- 
monly and are associated with high mortality rates, high length of stays, and high costs. 
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1035-146 Metformin Improves Endothelial Function in Patients 
With Metabolic Syndrome X 
Cristiana Vitale, Giuseppe Mercuro, Antonello Sikestri, Massimo Finl, Giuseppe M. 
w, San Raflaele, Roma, Italy, University of Cagliari, Caglian, Italy 
Metabolic Syndrome X (SX, hyperinsulinemia, hypertension, hyperlipemia) is associated 
with impaired endothelial function and increased risk of cardiovascular events. Insulin 
resistance plays an important role in the pathogenesis of endothelial dysfunction. The 
effects of metformtn, an antidiabetic agent that improves insulin sensitivity, on endothelial 
function have not been reported. 
The present study was designed to assess the effect of metformin on endothelial function 
in 65 patients with SX. 
Subjects with SX were allocated to receive metformin 500 mg twice daily (n = 32) or pla- 
cebo (n = 33) for 3 months. Before and after treatment endothelial function was assessed 
using flow mediated dilatation of the brachial artery using a high resolution vascular ultra- 
sound machine Whole-body insulin resistance was assessed on both occasions using 
the homeostasis model (HOMA-IR). 
Subjects who received metformin demonstrated statistically significant improvement in 
endothellum-dependent vasodrlation compared with those treated with placebo (p = 
0.0012 by P-way analysts of variance), whereas no significant effect was seen on endot- 
helium-independent response to sublingual GTN (p = 0.41). A significant improvement in 
Insulin resistance after metformln was observed (27% reduction in HOMA-IR, p < 0.01). 
and improvement in insulin resistance was associated wth improvement in endothelial 
function (r = -0.56, p < 0.01). 
In conclusion metformin improves both insulin resistance and endothelial function in 
patients with SX. This supports the concept of the central role of insulin resistance in the 
development of endothelial dysfunction in SX and the role of metformm for the treatment 
of these patients 
1035-147 Raloxifene Effect on Endothelial Function Depends on 
Duration of Menopause and Previous Hormone Use 
Giuseppe M. Rosano, Otavio Gebara, Cristiana Vitale, Mauricio Wajngarten, Antonello 
Silvestri, Josh Antonio F. Ramires, San Raffaele, Roma, Italy, INCOR, Sao Paula, Brazil 
Ovarian hormone deficiency reduces endothelial function in post-menopausal wmen 
(PMW). 
This effect is reversed by hormone and estrogen replacement therapy. Recent studies 
however have questioned the cardioprotective effect of hormone therapy in PMW. 
Recently a new class of agents the selective estrogen receptor modulators have been 
proposed for the treatment of PMW and one of these drugs (Raloxifene, R) is currently 
bema tested in a multicenter studv in order to assess its cardloprotective effect. The 
effect of R on endothelial function of PMW is controversial, studies in younger PMW 
showed an imDrovement of flow mediated dilatation (FMDI while other studies in older 
PMW failed to find such an effect on FMD suggesting that the effect of R IS age-depen- 
dent. The aim of the present study was to evaluate: 1) if the effect of R on endothelial 
function is age-dependent; 2) if the vasodilator effect of R is related to a previous expo- 
sure to estrogen replacement therapy. 
To this end we studied endothellal function by means of FMD in 39 PMW aging from 49 
to 75 years before and after 3 months of therapy with R 60 mg. R administration 
improved FMD (35112% ~~0.05 compared to baseline). In never estrogen users an 
inverse correlation was found between time from menopause and the effect of R on FMD 
(r=-58, p<O.Ol). 
In PMW >60 years who received estrogen replacement therapy in the past R increased 
